# A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

> **NCT04907539** · PHASE2 · COMPLETED · sponsor: **Redx Pharma Ltd** · enrollment: 25 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** RXC004
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Denosumab

## Key facts

- **NCT ID:** NCT04907539
- **Lead sponsor:** Redx Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-08
- **Primary completion:** 2024-04-02
- **Final completion:** 2024-04-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04907539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04907539, "A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT04907539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*